Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
<< View More Conferences

IASLC 18th World Conference on Lung Cancer

Oncology Conference Multimedia
View more videos >>
Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer
Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer
Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer
Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer
Dr. Camidge on the Unmet Needs for Lung Cancer
Dr. Camidge on the Unmet Needs for Lung Cancer
Oncology Conference Articles
Frontline Pembrolizumab More Than Doubles OS in PD-L1+ NSCLC
Frontline Pembrolizumab More Than Doubles OS in PD-L1+ NSCLC
Two-year results showed that frontline pembrolizumab (Keytruda) more than doubled median overall survival compared with standard chemotherapy in patients with high PD-L1 expressing non–small cell lung cancer
Ado-Trastuzumab Emtansine Shows Activity in HER2-Mutated, Amplified Lung Cancer
Ado-Trastuzumab Emtansine Shows Activity in HER2-Mutated, Amplified Lung Cancer
Ado-trastuzumab emtansine (Kadcyla) is active and well tolerated in patients with advanced HER2-mutant or amplified lung cancers as identified by next generation sequencing.
Entrectinib Impresses for ROS1-Positive NSCLC
Entrectinib Impresses for ROS1-Positive NSCLC
Treatment with entrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with ROS1 fusion-positive advanced non–small cell lung cancer.
Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC
Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC
The potent small molecule TKI ensartinib has shown promise and meaningful intercranial activity in ALK-positive, TKI-naïve patients with non–small cell lung cancer.
Frontline Lorlatinib Induces 90% Response in ALK+ NSCLC
Frontline Lorlatinib Induces 90% Response in ALK+ NSCLC
Lorlatinib induced an objective response rate of 90% in treatment-naïve patients with ALK-positive non–small cell lung cancer.
Durvalumab Delivers on QoL Post Chemo RT in PACIFIC Trial
Durvalumab Delivers on QoL Post Chemo RT in PACIFIC Trial
Patient reported outcomes from the PACIFIC trial of durvalumab versus placebo after chemoradiation in locally advanced unresectable NSCLC show that durvalumab had no serious impact on quality of life.
ctDNA EGFR Testing Identifies Proper Patients for Frontline Osimertinib
ctDNA EGFR Testing Identifies Proper Patients for Frontline Osimertinib
There was a high concordance between central tissue and plasma circulating tumor DNA testing for EGFR mutations in patients enrolled in the phase III FLAURA study of frontline osimertinib (Tagrisso) in NSCLC.
MET/EGFR Combo Effective for Advanced NSCLC
MET/EGFR Combo Effective for Advanced NSCLC
The combination of osimertinib and the MET inhibitor savolitinib showed signs of efficacy for pretreated patients with MET-positive, EGFR-mutant non–small cell lung cancer.
Dacomitinib Stands Out in EGFR-Mutated Subtype Response
Dacomitinib Stands Out in EGFR-Mutated Subtype Response
Second-generation EGFR inhibitor dacomitinib showed clear superiority over first-generation TKI gefitinib (Iressa) in a comparison of performance in EGFR mutation subtypes exon 19 deletion and L858R in advanced NSCLC.
Ramucirumab Associated With OS Benefit in Aggressive NSCLC
Ramucirumab Associated With OS Benefit in Aggressive NSCLC
Ramucirumab (Cyramza) plus docetaxel demonstrated an overall survival benefit versus placebo plus docetaxel in patients with advanced NSCLC whose disease rapidly progressed on first-line therapy,
Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC
Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC
A lower dose of ceritinib taken with a low-fat meal showed similar efficacy with fewer dose reductions and less severe gastrointestinal adverse events versus a 750-mg dose taken without food for patients with untreated ALK-positive metastatic non­–small cell lung cancer.
Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden
Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced an objective response rate of 46% in patients with recurrent small cell lung cancer with high tumor mutation burden, according to an exploratory analysis from the phase I/II CheckMate-032 study.
FISHing for a Better Assay in ALK-Positive Lung Cancer
FISHing for a Better Assay in ALK-Positive Lung Cancer
In addition to proving the superiority of alectinib versus crizotinib, the phase III ALEX trial provided clear guidance on which of 2 assays evaluated could provide stronger guidance on which patients would respond to ALK-specific therapy.
IASLC Conference Will Highlight PACIFIC Trial QoL Data on Durvalumab
IASLC Conference Will Highlight PACIFIC Trial QoL Data on Durvalumab
Fred R. Hirsch, MD, PhD, provides highlights of the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer, leading with his excitement for updated quality-of-life data from the PACIFIC trial of patients with locally advanced, unresectable stage III non–small cell lung cancer.
Publication Bottom Border
Border Publication
 
x